Neutrophil-derived leukotriene B4 is required for inflammatory arthritis by Chen, Mei et al.
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
BRIEF DEFINITIVE REPORT
JEM © The Rockefeller University Press  $8.00
Vol. 203, No. 4,  April 17, 2006  837–842  www.jem.org/cgi/doi/10.1084/jem.20052371
837
The clinical hallmarks of rheumatoid arthritis, a 
prevalent disease that aff  ects 1% of the popula-
tion, include polyarticular joint infl  ammation 
with leukocytic recruitment into synovial fl  uid 
and tissue, hyperplasia of the synovial joint lin-
ing, and development of synovial pannus that 
is erosive into cartilage and bone. Mechanisti-
cally, strong evidence implicates autoreactive 
lymphocytes and antibodies in disease patho-
genesis, yet the eff  ector mechanisms recruited 
to engender synovial infl  ammation remain ob-
scure. From a cellular standpoint, the rheuma-
toid arthritis synovium is variably populated 
with numerous leukocytic lineages; lympho-
cytes, plasma cells, macrophages, neutrophils, 
and mast cells are all present. Furthermore, the 
infl  ammatory synovial fl  uid contains dramati-
cally elevated numbers of leukocytes comprised 
predominantly of neutrophils (1–3). Function-
ally, although macrophages appear to provide 
a substantial source of proinfl  ammatory cyto-
kines, the contribution of other leukocyte 
  populations to synovial infl  ammation remains 
largely speculative. In addition to cytokines, 
the leukotrienes are among the infl  ammatory 
mediators expressed in the infl  amed  joint. 
  Indeed, previous analyses document marked 
  elevation of both leukotriene B4 (LTB4) and the 
cysteinyl leukotrienes in diseased joints (2, 4).
The murine K/BxN serum transfer model 
has provided insight into the pathogenic mec-
hanisms contributing to the eff  ector phase of 
  autoimmune synovitis. Distal symmetric erosive 
polyarthritis in K/BxN transgenic mice pro-
ceeds from pathogenic autoantibodies generated 
from interaction between T and B lymphocytes 
via the MHC class II molecule Ag7. Autoim-
mune interactions in the adaptive immune sys-
tem thus constitute proximal pathogenic events 
in disease development. The eff  ector phases of 
this autoantibody-mediated arthritis, which can 
evolve in the absence of lymphocytes, can be 
induced by passive transfer of IgG containing 
  serum to recipient mice (5). Essential eff  ector 
phase mechanisms elucidated thus far include 
the complement anaphylatoxin C5a, FcγRIII, 
TNF, and IL-1 receptor 1 (including by infer-
ence, IL-1; references 6 and 7). From a cellular 
standpoint, mast cells and neutrophils are essen-
tial, with an additional role for NK-T cells and 
down-modulating activity demonstrated for 
macrophages (8–12). These insights notwith-
standing, the proinfl  ammatory mediators contri-
buted by these lineages remain elusive. Herein, 
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we demonstrate a critical contribution of neutrophil-derived 
LTB4 to arthritis induction and perpetuation in the K/BxN 
serum transfer model of infl  ammatory arthritis.
RESULTS AND DISCUSSION
Leukotrienes are present in arthritic joints
To determine whether arthritic K/BxN joint tissues demon-
strate elevated LTB4 levels and thereby mimic human arthritis 
pathophysiology, we assayed leukotriene concentrations in 
joint tissues from arthritic and control nonarthritic mice. 
As shown in Fig. 1 (A and B), signifi  cantly elevated LTB4 and 
cysteinyl leukotriene C4 (LTC4) levels (161 ± 20 pg LTB4 
and 139 ± 9 pg LTC4 per gram ankle tissue) were detected in 
joint tissues from K/BxN mice with chronic arthritis. No 
leukotrienes were reproducibly detected in joint tissue from 
nonarthritic C57BL/6 mice. To assess a temporal relationship 
between the generation of leukotrienes and the development 
of clinical arthritis, we performed a time-course analysis of 
joint LTB4 levels after the administration of arthritogenic 
K/BxN serum. Indeed, ankle tissues show increasing concen-
trations of LTB4 that correlate strongly with increasing arthritis 
severity through disease establishment (Fig. 1 C).
Leukotriene defi  cient mice are resistant to arthritis
Elevated tissue levels of leukotrienes in arthritic mice 
prompted genetic exploration of a role for leukotrienes in 
K/BxN serum transfer arthritis. Because leukotriene synthesis 
proceeds via conversion of arachidonic acid to leukotriene 
A4 (LTA4) through coordinate enzymatic modifi  cation by 
the enzyme 5-lipoxygenase (5-LO) and the 5-LO activating 
protein, we assessed arthritic responses to arthritogenic 
K/BxN serum in mice defi   cient in the 5-LO enzyme. 
In contrast to WT control mice, 5-LO null mice are remark-
ably resistant to development of K/BxN serum–induced in-
fl  ammatory arthritis (Fig. 2 A). Infl  ammation, bone erosion, 
and cartilage erosion assessed histomorphometrically confi  rm 
clinical fi  ndings in 5-LO null mice. Whereas WT mice dem-
onstrate synovial hyperplasia, leukocytic infi  ltration, and pres-
ence of synovial erosion into bone and cartilage, 5-LO null 
joint tissues demonstrate a normal appearance, with little evi-
dence of these infl  ammatory changes (Fig. 2, D and G).
Having identifi  ed a critical requirement for leukotrienes 
in K/BxN serum transfer arthritis, we sought to defi  ne the 
leukotriene species mediating this pathogenic event. Subse-
quent to synthesis of the unstable intermediate LTA4, further 
metabolism to potently bioactive leukotriene metabolites can 
proceed either by conjugation to glutathione to form the cys-
teinyl leukotrienes (LTC4, LTD4, and LTE4) or hydrolysis to 
form LTB4. The enzyme leukotriene C4 synthase (LTC4S) 
catalyzes the conjugation of glutathione to LTA4 to form 
LTC4 and thus is required for the generation of all cysteinyl 
leukotrienes. Potent bioactivities of the cysteinyl leukotrienes 
relevant in infl  ammatory arthritis include induction of vaso-
dilation and increased vascular permeability, as well as stimu-
lation of cytokine secretion from mast cells (13, 14). To assess 
a role for cysteinyl leukotrienes in induction of K/BxN   serum 
transfer infl   ammatory arthritis, we examined the arthritic 
  responses in LTC4S null mice. Interestingly, we fi  nd that 
these mice demonstrate robust clinical evidence of arthritis 
(Fig. 2 B). Histomorphometric scoring of infl  ammation, bone 
erosion, and cartilage erosion confi  rms clinical fi  ndings with 
prominent leukocytic infi  ltration and synovial hyperplasia in 
both WT and LTC4S null mice (Fig. 2, E and H). Thus, 
  synovial infl  ammation may proceed in the absence of the 
  cysteinyl leukotrienes.
LTA4 hydrolase (LTA4H) catalyzes the hydrolysis of the 
unstable epoxide intermediate LTA4 to LTB4. Among the 
bioactivities attributable to LTB4 are increased vascular per-
meability, potent leukocyte chemoattraction, induction of 
vascular adhesion molecule expression, and stimulation of 
neutrophil degranulation (15). Thus, LTB4 was a prominent 
candidate eff  ector molecule for participation in this neutro-
phil-dependent arthritis model. Indeed, LTA4H null mice are 
remarkably resistant to K/BxN serum transfer arthritis (Fig. 
2 C). Histomorphometric analyses concur with clinical ob-
servations (Fig. 2, F and I), as LTA4H null mice demonstrate 
little evidence of the leukocytic infi   ltration or synovial 
  hyperplasia apparent in WT mice. Thus, these data demon-
strate that the requirement for leukotrienes in this model is a 
requirement for LTB4.
Treatment of arthritis via leukotriene inhibition
To independently confi  rm a critical role for leukotrienes in ar-
thritis induction after K/BxN serum transfer, we used a phar-
macologic inhibitor of 5-LO. Mice were orally administered 
Figure 1.  Quantifi  cation of leukotrienes in arthritic joint tissues. 
LTB4 (A) or LTC4 (B) was quantifi  ed in ankle tissues from arthritic K/BxN 
mice (n = 5) or control B6 mice (n = 10). Values depicted are means ± 
SEM of three independent experiments (P < 0.001). Dotted line represents 
lower limit of assay sensitivity. (C) Kinetics of LTB4 production in arthritic 
joint tissue. B6 mice were administered arthritogenic K/BxN serum and 
killed at 2-d increments thereafter for quantifi  cation of ankle tissue LTB4 
(bars). Clinical arthritis was measured throughout the experimental course 
(◆). Data represent means ± SEM of fi  ve mice per time point in three 
separate experiments.JEM VOL. 203, April 17, 2006  839
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either 5-LO inhibitor (L-739,010; 250 mg/kg, twice daily) 
or carrier control beginning 2 d before K/BxN serum injec-
tion (16). 5-LO activity was assessed at pharmacologic peak 
and trough on peripheral blood leukocytes to confi  rm that 
blockade of leukotriene synthesis was achieved with this 
  regimen (see Supplemental Materials and methods and Fig. 
S1, available at http://www.jem.org/cgi/content/full/jem. 
20052371/DC1). Consistent with our genetic observations, 
oral administration of the 5-LO inhibitor eff  ectively prevents 
induction of arthritis (Fig. 3, A and B). Histologically, 5-LO 
inhibitor–pretreated mice display little evidence of leukocytic 
infi  ltrate, synovial hyperplasia, or joint erosions, whereas 
  control mice display marked arthritic activity (Fig. 3 C).
Mechanistically, genetic approaches using knockout mice 
are limited to defi  ning a role for leukotrienes in disease in-
duction. An ongoing role in disease perpetuation remained 
undefi  ned. We therefore used the 5-LO pharmacologic in-
hibitor to defi  ne an ongoing role for leukotriene synthesis 
  after establishment of K/BxN serum transfer arthritis. Here, 
mice were administered K/BxN serum and allowed to de-
velop robust clinical evidence of arthritis. These arthritic 
mice were thereafter administered either 5-LO inhibitor or 
vehicle control and monitored for clinical arthritis activity. 
We fi  nd that administration of the 5-LO inhibitor decreases 
clinical arthritis to  20% of that evident in control vehicle–
treated mice at 14 d after arthritis induction (Fig. 3, A and B). 
Histologic examination reveals decreased tissue infl  amma-
tion, synovial hyperplasia, and erosive activity (Fig. 3 C). 
  Focusing on the striking decline in leukocytic infi  ltration in 
synovial tissues of 5-LO inhibitor–treated mice, we quantifi  ed 
synovial tissue neutrophils in treated and control mice (Fig. 
3 D). We observe a profound decline in synovial neutrophil 
numbers to 26% of control mice after inhibition of 5-LO. 
This decrease in neutrophil numbers accounts for 87% of the 
total decrease in synovial cellularity (not depicted), suggesting 
that neutrophil recruitment comprises a prominent activity of 
LTB4 in the established phase of K/BxN arthritis. This asser-
tion is supported by the ongoing requirement for the LTB4 
receptor, BLT1, on neutrophils in established arthritis and by 
the therapeutic effi   cacy of a BLT1 antagonist for ameliorating 
K/BxN arthritis (17).
Leukocytes contribute leukotriene synthetic function
We next sought to defi  ne cellular sources of leukotriene 
synthesis in infl  amed synovium. 5-LO expression is lim-
ited predominantly to leukocyte populations; however, 
there are reports of 5-LO activity in nonhematopoietic 
lineages. To focus our analyses, we used radiation chime-
ric mice and found that arthritogenic 5-LO synthetic 
  activity derives exclusively from a BM lineage (Fig. 4 A 
and Fig. S2, available at http://www.jem.org/cgi/ content/
full/jem.20052371/DC1).  Because analyses of BM lin-
eage–specifi  c studies demonstrate critical requirements for 
mast cells and neutrophils in K/BxN arthritis, we specifi  -
cally explored the contribution of leukotriene synthetic 
function from these lineages. To assess a requirement 
for synovial mast cell 5-LO activity, we used a modifi  ca-
tion of the genetic approach used previously to demon-
strate that synovial mast cells   contribute to K/BxN 
arthritis pathogenesis in mast cell–  defi  cient W/Wv mice 
Figure 2.  LTB4-defi  cient mice are resistant to arthritis. Arthritis 
responses in 5-LO null (A), LTC4S null (B), LTA4H null (C), and control mice. 
n = 5 mice/group/experiment, representative of three experiments. 5-LO 
null and LTA4H null versus WT, P < 0.001. (D–F) Histomorphometric 
arthritis quantifi  cation from 5-LO null (D), LTC4S null (E), and LTA4H null 
(F) mice. P < 0.001, 5-LO null and LTA4H null. (G–J) Histologic sections 
from 5-LO null (G), LTC4S null (H), LTA4H null (I), and WT (J) mice at experi-
mental day 14. Bar, 100 μm. S, synovium; C, cartilage; Bn, bone.840  NEUTROPHIL-DERIVED LTB4 IN ARTHRITIS | Chen et al. 
(8).   Interestingly, 5-LO null mast cell–engrafted W/Wv 
mice demonstrate the same degree of arthritic response as 
W/Wv mice engrafted with WT mast cells (Fig. 4 B). 
Thus, mast cells are not a critical cellular source of arthri-
togenic LTB4.
Neutrophils contribute to arthritis via LTB4 production
To defi  ne a functional role for neutrophil leukotriene pro-
duction in K/BxN serum transfer arthritis induction, we 
adoptively transferred WT neutrophils into 5-LO null 
  recipients. Indeed, we fi  nd that neutrophils can function-
ally complement leukotriene defi  ciency, restoring  83% of 
  arthritic activity (Fig. 4 C and Fig. S3, available at http://
www.jem.org/cgi/content/full/jem.20052371/DC1). Con-
fi  rming that the relevant role of neutrophils in this system 
is to provide LTB4, we found that coadministration of the 
5-LO inhibitor completely inhibits arthritic activity from 
adoptively transferred neutrophils, the only source of 5-LO 
activity in recipient mice (Fig. S4, available at http://www.
jem.org/cgi/content/full/jem.20052371/DC1). To establish 
that WT donor neutrophils may contribute locally to synovi-
tis, we transferred WT congenic CD45.1 donor neutrophils 
into 5-LO null mice (CD45.2 background). Indeed, immuno-
fl   uorescence analysis of arthritic recipient 5-LO–defi  cient 
  synovial tissues reveals abundant WT donor neutrophils as 
well as recipient neutrophils in the disease lesion (Fig. 4 H).
In addition to defi  ning a critical, ongoing requirement 
for LTB4 in the eff  ector phase of synovial infl  ammation in 
the K/BxN model, these fi  ndings establish a novel mecha-
nistic contribution of neutrophils to autoimmune disease. 
Typically, neutrophils are envisaged as a responding lin-
eage, recruited via chemoattractants such as LTB4 to pro-
vide pathogen-destroying eff  ector functions as part of an 
innate immune response. Here, we demonstrate that neu-
trophils contribute essentially to the establishment of the 
autoimmune infl  ammatory lesion via synthesis of LTB4, in-
citing disease through the potent bioactivities of this lipid 
infl  ammatory mediator.
Figure 3.  5-LO inhibitor (L-739,010) ameliorates arthritis. 
(A and B) L-739,010 administered either as pretreatment (fi  lled arrow) or as a 
therapeutic regimen (open arrow). n = 5 mice/group/experiment, repre-
sentative of three experiments. P < 0.001 pretreatment versus mock-
treated mice; P < 0.01 treatment versus vehicle. (C) Histomorphometric 
quantifi  cation of arthritis at experimental day 14. P < 0.01–0.001. 
(D) Quantifi  cation of neutrophil accumulation per 0.1-mm2 synovial 
area. n = 5 mice/group/experiment, 20–25 fi  elds/mouse, representative 
of three experiments. P < 0.01, pretreated and treated versus 
mock treatment.
Figure 4.  Neutrophils are a cellular source of synovial arthrito-
genic leukotrienes. (A) 5-LO activity derived from BM lineages. Lethally 
irradiated (iRAD) recipient mice were reconstituted with donor BM as 
labeled. n = 5 mice/group/experiment, representative of three experi-
ments. P < 0.001. (B) Mast cell 5-LO activity is dispensable for arthritis 
induction. Mast cell–defi  cient W/Wv mice were engrafted as labeled and 
assessed for arthritic response. n = 10–12 mice/group, P < 0.001, WT 
and 5-LO null BM-derived mast cell versus W/Wv mice. (C) Neutrophils 
provide arthritogenic LTB4. Purifi  ed neutrophils from WT mice were trans-
ferred daily for 5 d into 5-LO null recipient mice. n = 5 mice/group/ 
experiment, representative of three experiments. P < 0.05. (D–H) WT 
donor neutrophils (CD45.1) in recipient 5-LO null joint tissues (CD45.2). 
Shown are: (D) hematoxylin/eosin stain, (E) isotype control, (F) CD45.1 
(green), (G) Gr-1 (red), and (H) merge CD45.1 and Gr-1 with nuclear strain 
(blue). Bar, 25 μm.JEM VOL. 203, April 17, 2006  841
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These fi  ndings confi  rm and extend previous observations 
regarding the role of leukotrienes (18–20) and neutrophils in 
animal models of arthritis and may provide insight into human 
infl  ammatory disease. In infl  ammatory arthritis, the articular 
cavity can become dramatically infi  ltrated with neutrophils, 
with a turnover estimated at a billion cells per day in a sin-
gle joint (1–3). Yet their role in pathogenesis is incompletely 
understood. Are they simply responding to chemoattractants 
generated by other (e.g., autoreactive) cells, or do they have a 
more primary role in promoting infl  ammation within the con-
fi  nes of the joint? Although both roles may in fact contribute 
to disease, our fi  ndings lend mechanistic support to the possi-
bility that neutrophils within the joint may participate directly 
in infl  ammation via elaboration of LTB4. This possibility is 
consistent with the marked elevation of LTB4 in neutrophil-
rich synovial eff  usions (2). Because the notion of neutrophils as 
instigators of disease has not been extensively explored, in part 
because of the technical limitations of working with this lin-
eage, these lessons have broad import for human autoimmune 
disease. Further attention to neutrophils promises surprising 
insights into their contributions to diverse autoimmune condi-
tions, aiding identifi  cation of novel direct targets of therapy.
MATERIALS AND METHODS
Mice. 6–10-wk-old mice were used for these studies. C57BL/6J, B6.SJL-
  Ptprca Pep3b/BoyJ (CD45.1 allele), and WBB6F1-W/Wv mice were pur-
chased from The Jackson Laboratory, and 129SvEv mice were purchased 
from   Taconic. 5-LO null mice (N10 backcross to B6; reference 21), LTA4H 
null mice (129SvEv background; provided by B.H. Koller, University of 
North Carolina Chapel Hill, Chapel Hill, NC; reference 22), and LTC4S null 
mice (N5 backcross to B6; reference 23) were bred locally. K/BxN mice were 
maintained as described previously (5). All procedures were approved by the 
Dana-Farber Cancer Institute Institutional Animal Care and Use Committee.
Arthritis studies. Arthritogenic K/BxN serum was transferred to recipient mice,
and clinical arthritis responses were graded as described previously (5, 8, 24).
Measurement of tissue leukotrienes. Leukotriene levels in joint tissue 
homogenates were quantifi  ed using HPLC separation followed by ELISA 
measurement as described previously (23).
Pharmacologic inhibition of 5-LO. A 5-LO inhibitor, L-739,010 (2-cyano-
4-(3-furyl)-7-[[6-[3-(3-hydroxy-6,8-dioxabicyclo [3.2.1] octanyl)]2-pyridyl]
methoxy]naphthalene; provided by Merck Frosst Centre for Therapeutic 
Research; reference 16) was dissolved in 1% methylcellulose in PBS (Sigma-
Aldrich) and administered orally via gavage twice daily. The dose used, 250 
mg/kg, was chosen based on the previously defi  ned pharmacokinetic profi  le 
of l-739,010 in mice. A vehicle control (1% methylcellulose) was adminis-
tered orally in the same volume and frequency to control mice.
Generation of radiation BM chimeras. Recipient mice were lethally 
  irradiated with split doses (500 and 450 cGy), transplanted with donor BM, 
and supported with oral antibiotic (Baytril). Arthritis experiments were per-
formed after allowing 8 wk for transplant engraftment.
BM-derived mast cell cultures and mast cell engraftment. BM-
  derived mast cells were generated and engrafted into mast cell–defi  cient 
W/Wv recipients as described previously (8).
BM neutrophil isolation and engraftment. Isolation of mature neu-
trophils from BM was accomplished using discontinuous Percoll density 
centrifugation (25). Mature neutrophils were recovered at the interface of 
the 65 and 75% fractions. Neutrophil purity (>90%) was determined both 
morphometrically by Diff  -Quik staining and cytofl  uorometric   expression 
of Gr-1 (Fig. S3). 5-LO null recipient mice were administered 107 
neutrophils via tail vein injection on days 0, 1, 2, 3, and 4 after K/B x N 
serum transfer.
Histological examination and quantifi  cation of neutrophil accumu-
lation of murine synovial tissues. Arthritis changes in joint tissues were 
graded based on the scoring system used by Pettit et al. (26) with minor 
modifi  cations. Specifi  cally, cartilage was scored using the following criteria: 
0, no cartilage injury; 1, synovial adherence to margins of cartilage in fewer 
than three sites; 2, synovial adherence to margins of cartilage in three or 
more sites; 3, synovial adherence to cartilage not limited to margins but no 
full-thickness injury (damage does not extend beyond tidemark); 4, full-
thickness injury in fewer than three sites; 5, full-thickness injury in three or 
more sites. To quantify synovial neutrophil accumulation of murine synovial 
tissues, total neutrophil numbers were calculated by counting cells with 
polymorphonuclei morphology in 0.1-mm2 sections of synovium. A mini-
mum of eight sections per mouse and fi  ve reticule-defi  ned regions (0.1 mm2) 
per section were assessed. Immunofl  uorescence histology of joint tissues was 
performed as described previously (24) with the following directly conju-
gated mAbs: FITC anti-CD45.1 antibody (clone A20; SouthernBiotech), 
FITC anti-IgG2a antibody (SouthernBiotech), PE anti–Gr-1 antibody 
(clone RB6-8C5; Caltag Laboratories), and PE anti-IgG2b antibody (Caltag 
Laboratories). Tissue sections were examined under a Nikon TE2000-U in-
verted fl   uorescence microscope equipped with a high resolution Sony 
ICX285 Cooled CCD digital camera.
Statistical analysis. Data are presented as the mean ± SEM. Statistical sig-
nifi  cance for comparisons between groups was determined using Student’s 
paired two-sample t test or ANOVA followed by Bonferroni correction.
Online supplemental material. Fig. S1 confi  rms the inhibition of 5-LO 
activity via oral administration of L-739,010 through ex vivo assay of whole 
blood leukocytes. Fig. S2 demonstrates the degree of BM engraftment in 
radiation chimeric mice. Fig. S3 shows neutrophil purifi  cation for adop-
tive transfer. Fig. S4 verifi  es that adoptively transferred neutrophils supply 
5-LO activity for arthritis restoration. Online supplemental material, includ-
ing Supplemental Materials and methods, is available at http://www.jem.
org/cgi/content/full/jem.20052371/DC1.
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